Complete second quarter 2015 financial results will be announced on
Tuesday, August 4, 2015
IRVINE, Calif.--(BUSINESS WIRE)--Jul. 21, 2015--
Masimo Corporation (NASDAQ: MASI) today announced certain preliminary
financial results for the second quarter ended July 4, 2015.
While Masimo’s financial results for the quarter will not be final until
earnings are fully announced on August 4, 2015, Masimo expects that its
product revenue for the second quarter of 2015 will range from $147.0
million to $148.0 million, and that its royalty revenue for the quarter
will be approximately $8.0 million. As a result, Masimo now expects its
total second quarter revenues to range from $155.0 million to $156.0
million. Masimo also estimates that its second quarter of 2015
fully-diluted GAAP earnings per share will be between $0.35 and $0.36.
The preliminary financial information presented in this press release is
based on Masimo’s current expectations and may be adjusted as a result
of, among other things, completion of customary quarterly review
procedures. Management plans to discuss Masimo’s complete second quarter
2015 financial results after the market closes on Tuesday, August 4,
2015.
Details for Second Quarter 2015 Financial Results Conference Call
The conference call to review Masimo’s complete financial results for
the second quarter ended July 4, 2015 will begin at 1:30 p.m. PT (4:30
p.m. ET) on August 4, 2015 and will be hosted by Joe Kiani, Chairman and
Chief Executive Officer, and Mark P. de Raad, Executive Vice President
and Chief Financial Officer.
A live webcast of the conference call will be available online from the
investor relations page of the company’s corporate website at www.masimo.com.
The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706)
758-3929 for international callers. The reservation code for both
dial-in numbers is 84990153. After the live webcast, the call will be
available on Masimo’s website through September 1, 2015. In addition, a
telephonic replay of the call will be available through August 18, 2015.
The replay dial-in numbers are (800) 585-8367 for domestic callers and
+1 (855) 859-2056 for international callers. Please use reservation code
84990153.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies that significantly improve patient care-helping
solve “unsolvable” problems. In 1995, the company debuted
Measure-Through-Motion and Low-Perfusion™ pulse oximetry,
known as Masimo SET®, which virtually eliminated false alarms
and increased pulse oximetry’s ability to detect life-threatening
events. More than 100 independent and objective studies have shown that
Masimo SET® outperforms other pulse oximetry technologies,
even under the most challenging clinical conditions, including patient
motion and low peripheral perfusion. In 2005, Masimo introduced rainbow
SET® Pulse CO-Oximetry technology, allowing noninvasive and
continuous monitoring of blood constituents that previously could only
be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and Pleth Variability Index (PVI®),
in addition to SpO2, pulse rate, and perfusion index (PI). Additional
information about Masimo and its products may be found at www.masimo.com.
Forward-Looking Statements
All statements other than statements of historical facts included in
this press release that address activities, events or developments that
we expect, believe or anticipate will or may occur in the future are
forward-looking statements including, in particular, the statements
about our expectations for second quarter 2015 product revenues, royalty
revenue, total revenues and earnings per share. These forward-looking
statements are based on management’s current expectations and beliefs
and are subject to uncertainties and factors, all of which are difficult
to predict and many of which are beyond our control and could cause
actual results to differ materially and adversely from those described
in the forward-looking statements. These risks include, but are not
limited to, those related to: completion of customary quarterly review
procedures impacting, among other items, currently assumed product gross
profit margins, operating expenses, other income and expense, effective
tax rate and weighted average shares outstanding; and other factors
discussed in the “Risk Factors” section of our most recent periodic
reports filed with the Securities and Exchange Commission (“SEC”),
including our most recent Form 10-K and Form 10-Q, all of which you may
obtain for free on the SEC’s website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof, even if subsequently made available by us on our website or
otherwise. We do not undertake any obligation to update, amend or
clarify these forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required under
applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome
and Reducing Cost of Care... by Taking Noninvasive Monitoring to New
Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are
trademarks or registered trademarks of Masimo.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150721005538/en/
Source: Masimo Corporation
Masimo Corporation
Investors:
Eli Kammerman,
949-297-7077
ekammerman@masimo.com
or
Media:
Irene
Paigah, 858-858-7001
irenep@masimo.com